Actinogen Medical Limited (DE:3AC)

FRANKFURT:3AC

3AC

Actinogen Medical

RESEARCH TOOLSreports

Actinogen Medical (3AC) Price & Analysis

0 Followers

3AC Stock Chart & Stats

€0.02

€0.00(0.00%)

At close: Jan 08 4:00 PM EST

€0.02

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€0.01 - €0.05

Previous CloseN/A

Volume0.00

Average Volume (3M)8.57K

Market Cap

€75.69M

Enterprise Value€119.44M

Total Cash (Recent Filing)€6.53M

Total Debt (Recent Filing)€366.31K

Price to Earnings (P/E)―

Beta0.43

Next Earnings

Aug 31, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding3,661,091,600

10 Day Avg. Volume1,000

30 Day Avg. Volume8,566

Financial Highlights & Ratios

PEG Ratio0.26

Price to Book (P/B)3.74

Price to Sales (P/S)12.48

P/FCF Ratio-9.03

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€0.05

Price Target Upside144.39% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)>-0.01

Revenue Forecast (FY)€3.39M

Bulls Say, Bears Say

Bulls Say

Lead Clinical Asset Xanamem Targeting CNS DisordersHaving a single, clearly defined lead molecule (Xanamem) with a specific mechanism (11β-HSD1 inhibition) focused on large CNS indications creates durable strategic optionality. Success in trials can unlock licensing, milestone and royalty revenue and concentrate resources on a high-impact program.

Low Leverage And Relatively Healthy Equity RatioLow financial leverage and a relatively healthy equity ratio reduce bankruptcy and interest-rate risk, preserving strategic flexibility. For a clinical-stage biotech, limited debt lowers compulsory cash outflows, helping prioritize R&D funding or partnership negotiations without heavy fixed obligations.

Business Model Oriented To Licensing/partnership MonetizationA licensing/partnering-focused model is structurally durable for small biotechs: it reduces the need for large commercial infrastructure, shifts commercialization risk to larger pharma partners, and offers milestone/royalty upside while allowing resource concentration on clinical proof-of-concept.

Bears Say

Negative Operating And Free Cash FlowSustained negative operating and free cash flows create structural funding pressure; the -13.01% decline in free cash flow growth signals worsening cash generation. Over months this forces dilution through capital raises or cuts to development, increasing execution and timeline risk for clinical programs.

Sharp Revenue Decline And Persistent LossesA 39% revenue drop and ongoing negative margins indicate the company is not generating commercial cash inflows to support operations. This structural weakness limits reinvestment capacity, depresses returns to shareholders, and elevates dependence on external financing to sustain clinical development.

No Material Recurring Product Revenue; Reliance On Capital RaisesDependence on periodic equity raises is a durable vulnerability: fundraising cycles can be dilutive, timing-sensitive, and market-dependent. This funding model raises the probability of capital gaps, which can delay trials or force unfavorable partnership terms, impacting long-term program progress.

Actinogen Medical News

Actinogen boosts director equity with new Employee Share Plan issue

Actinogen Medical ( ($AU:ACW) ) has provided an announcement. Actinogen Medical has disclosed a change in director Dr...

8h ago

Actinogen Medical Seeks ASX Quotation for 56 Million New Shares

Actinogen Medical ( ($AU:ACW) ) has shared an update. Actinogen Medical has applied to the ASX for quotation...

8h ago

Actinogen shareholders back all resolutions as Xanamem trials advance

Actinogen Medical ( ($AU:ACW) ) has shared an update. Actinogen Medical reported that all five resolutions put to...

1d ago

Actinogen Medical Seeks ASX Quotation for New Share Issue

Actinogen Medical ( ($AU:ACW) ) has provided an announcement. Actinogen Medical Limited has applied for quotation on the...

6d ago

Actinogen clears third safety review in pivotal Alzheimer’s trial

Actinogen Medical ( ($AU:ACW) ) just unveiled an update. Actinogen Medical said an independent Data Monitoring Committee has,...

7d ago

Actinogen wins aligned EMA and FDA backing for Xanamem Alzheimer’s path

An announcement from Actinogen Medical ( ($AU:ACW) ) is now available. Actinogen Medical has secured positive scientific advice...

28d ago

Actinogen Medical Seeks ASX Quotation for 66.7 Million New Shares

Actinogen Medical ( ($AU:ACW) ) just unveiled an update. Actinogen Medical has applied to the ASX for quotation...

1M ago

Actinogen convenes June shareholder meeting as Xanamem trials advance

The latest announcement is out from Actinogen Medical ( ($AU:ACW) ). Actinogen Medical has called a general meeting...

1M ago

Actinogen CEO Exercises Options as Key Alzheimer’s Trial Milestone Nears

Actinogen Medical ( ($AU:ACW) ) has shared an announcement. Actinogen Medical has highlighted that two tranches of unlisted...

1M ago

Actinogen CEO Steven Gourlay Boosts Shareholding Through Option Exercise

Actinogen Medical ( ($AU:ACW) ) just unveiled an update. Actinogen Medical has disclosed a change in director Dr...

1M ago

3AC FAQ

What was Actinogen Medical Limited’s price range in the past 12 months?

Actinogen Medical Limited lowest stock price was €0.01 and its highest was €0.04 in the past 12 months.

What is Actinogen Medical Limited’s market cap?

Actinogen Medical Limited’s market cap is €75.69M.

When is Actinogen Medical Limited’s upcoming earnings report date?

Actinogen Medical Limited’s upcoming earnings report date is Aug 31, 2026 which is in 68 days.

How were Actinogen Medical Limited’s earnings last quarter?

Actinogen Medical Limited released its earnings results on Feb 25, 2026. The company reported -€0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.002.

Is Actinogen Medical Limited overvalued?

According to Wall Street analysts Actinogen Medical Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Actinogen Medical Limited pay dividends?

Actinogen Medical Limited does not currently pay dividends.

What is Actinogen Medical Limited’s EPS estimate?

Actinogen Medical Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Actinogen Medical Limited have?

Actinogen Medical Limited has 3,661,091,600 shares outstanding.

What happened to Actinogen Medical Limited’s price movement after its last earnings report?

Actinogen Medical Limited reported an EPS of -€0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Actinogen Medical Limited?

Currently, no hedge funds are holding shares in DE:3AC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Actinogen Medical Stock Smart Score

Outperform

Fundamentals

Return on Equity

-134.14%

Trailing 12-Months

Asset Growth

-55.10%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Actinogen Medical Limited

Actinogen Medical Limited is an Australian biotechnology company dedicated to developing treatments for neurological and neuropsychiatric disorders linked to imbalanced brain cortisol levels. Their lead product, Xanamem, an inhibitor of the 11ß-HSD1 enzyme, is currently in Phase 2 clinical trials. This compound has demonstrated target engagement within the central nervous system and is being investigated for its potential in conditions such as Alzheimer's disease, depression with cognitive impairment, and the anxiety, sleep, and behavioral issues associated with fragile X syndrome. Founded in 1999, the company was formerly known as Actinogen Limited, adopting its current name in November 2015, and is headquartered in Sydney, Australia.

Actinogen Medical (3AC) Earnings & Revenues

Historic Earnings Reports

3AC Stock 12 Month Forecast

Average Price Target

€0.05

▲(144.39% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","1":"€1","-1":"-€1","-0.5":"-€0.5","0.5":"€0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.04887752,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€0.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.04887752,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€0.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.04887752,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€0.05</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.02,0.022221347692307693,0.024442695384615385,0.026664043076923077,0.02888539076923077,0.031106738461538462,0.03332808615384615,0.03554943384615385,0.03777078153846154,0.03999212923076923,0.04221347692307692,0.044434824615384616,0.04665617230769231,{"y":0.04887752,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.02,0.022221347692307693,0.024442695384615385,0.026664043076923077,0.02888539076923077,0.031106738461538462,0.03332808615384615,0.03554943384615385,0.03777078153846154,0.03999212923076923,0.04221347692307692,0.044434824615384616,0.04665617230769231,{"y":0.04887752,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.02,0.022221347692307693,0.024442695384615385,0.026664043076923077,0.02888539076923077,0.031106738461538462,0.03332808615384615,0.03554943384615385,0.03777078153846154,0.03999212923076923,0.04221347692307692,0.044434824615384616,0.04665617230769231,{"y":0.04887752,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.012,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.01,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.011,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.012,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.02,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.018,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.036,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.029,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.023,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.02,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.019,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.027,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.02,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >